Related Experiment Video

Updated: Jun 4, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Focal adhesion kinase as a therapeutic target of bortezomib

Bor-Sheng Ko1, Tzu-Ching Chang, Jun-Yang Liou

  • 1Institute of Cellular and System Medicine, National Health Research Institutes, Zhunan, Miaoli County, Taiwan.

Anti-Cancer Agents in Medicinal Chemistry
|January 29, 2011
PubMed

Insights

Bortezomib, a proteasome inhibitor, suppresses focal adhesion kinase (FAK) expression by blocking the NFκB pathway. This mechanism offers a potential strategy for inhibiting cancer growth and metastasis.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Bortezomib is an approved proteasome inhibitor for multiple myeloma and mantel cell lymphoma.
  • Emerging research indicates bortezomib's potential in treating solid tumors, alone or in combination therapies.
  • Focal adhesion kinase (FAK) activation is linked to malignant tumor progression and invasion.

Purpose of the Study:

  • To investigate the molecular mechanisms by which bortezomib affects FAK expression.
  • To explore the potential of targeting FAK with bortezomib as a strategy against cancer metastasis.
  • To review the molecular regulation of FAK and bortezomib's clinical applications.

Main Methods:

  • Analysis of FAK promoter sequences for NFκB and p53 binding domains.
  • Assays including FAK promoter activity, real-time PCR, electrophoretic mobility shift assay (EMSA), and chromatin immunoprecipitation (ChIP).

Main Results:

  • Bortezomib transcriptionally suppresses FAK expression via the nuclear factor kappa B (NFκB) pathway.
  • Bortezomib inhibits NFκB binding to the FAK promoter, leading to reduced FAK expression.
  • Suppression of FAK by bortezomib inhibits cancer cell growth, migration, and invasion.

Conclusions:

  • Bortezomib's ability to repress FAK expression presents a potential therapeutic strategy for preventing cancer metastasis.
  • Targeting FAK with bortezomib may be a viable approach for managing malignant tumors.
  • Further research into bortezomib and FAK interactions could yield novel cancer treatments.

More Related Videos

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...